Commonground
Senior Moderator
Posted on 26 Feb 2026
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies for public health emergencies. The award was issued under a multiple‑award Indefinite Delivery–Indefinite Quantity (IDIQ) contract. The collaboration is intended to strengthen U.S. pandemic preparedness.
Under this framework, the CDC can provide Cepheid early access to outbreak samples, genomic sequences, and critical reference materials. The objective is to bridge development gaps during the initial stages of pathogen emergence and accelerate the creation of next-generation diagnostic assays, enabling rapid and accurate testing as new threats arise. Cepheid states that its integrated PCR systems are designed to deliver fast results across diverse care settings while supporting real-time surveillance, early detection, and evidence-based decision-making.
The company cites its COVID-19 experience, when it launched the first point-of-care PCR test for SARS-CoV-2 in the United States within weeks of publication of the viral sequence, as evidence that development timelines can be compressed without sacrificing accuracy or quality. Within the IDIQ framework, Cepheid will contribute to efforts to modernize outbreak detection, accelerate diagnostic innovation, and maintain testing agility as threats evolve. The collaboration underscores the importance of public-private partnerships in enabling rapid scale-up and strengthening operational readiness.
continued: https://mobile.labmedica.com/indust...en-us-pandemic-testing-preparednesss.amp.html
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies for public health emergencies. The award was issued under a multiple‑award Indefinite Delivery–Indefinite Quantity (IDIQ) contract. The collaboration is intended to strengthen U.S. pandemic preparedness.
Under this framework, the CDC can provide Cepheid early access to outbreak samples, genomic sequences, and critical reference materials. The objective is to bridge development gaps during the initial stages of pathogen emergence and accelerate the creation of next-generation diagnostic assays, enabling rapid and accurate testing as new threats arise. Cepheid states that its integrated PCR systems are designed to deliver fast results across diverse care settings while supporting real-time surveillance, early detection, and evidence-based decision-making.
The company cites its COVID-19 experience, when it launched the first point-of-care PCR test for SARS-CoV-2 in the United States within weeks of publication of the viral sequence, as evidence that development timelines can be compressed without sacrificing accuracy or quality. Within the IDIQ framework, Cepheid will contribute to efforts to modernize outbreak detection, accelerate diagnostic innovation, and maintain testing agility as threats evolve. The collaboration underscores the importance of public-private partnerships in enabling rapid scale-up and strengthening operational readiness.
continued: https://mobile.labmedica.com/indust...en-us-pandemic-testing-preparednesss.amp.html